colchicine effect on persistent dyspnea in COVID19

Effects of colchicine on persistent dyspnea and pulmonary fibrosis of COVID-19 patients after hospital discharge

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200707048047N1

Enrollment

Registered

2021-03-27

Start date

2020-07-22

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID19. U07.1

Interventions

Intervention group: patients with history of Covid19 infection with persistent dyspnea and pulmonary fibrosis receive colchicine 0.5mg BID for 3 days and then 0.5 mg daily for 1 month.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: history of covid19 infection confirmed with lung lesion in CT scan and/or positive PCR

Exclusion criteria

Exclusion criteria: history of taking colchicine..history of ipf.non consent pregnancy history of allergic reaction to colchicine immunosuppressive drug consumption history of chronic dyspnea or dyspnea on exertion due to underlying diseases non consent in any stage of study

Design outcomes

Primary

Measure	Time frame
???? ???? ??? ?? ???? ???? ???? UCSD. Timepoint: Before intervention,1and6months after intervention. Method of measurement: UCSD questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactmasoumeh moallem

Islamic Azad University

masoumehmoallem@gmail.com+98 21 2222 3567

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026